Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis

Annals of Neurology

Volumn 40, Issue 6, 1996, Pages 846-852

  Leppert, David ^a   Waubant, Emmanuelle ^b   Bürk, Martin R ^a   Oksenberg, Jorge R ^b   Hauser, Stephen L ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GELATINASE A; GELATINASE B; INTERFERON BETA SERINE; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; PHYCOERYTHRIN; PHYTOHEMAGGLUTININ; RECOMBINANT INTERLEUKIN 2;

ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE MIGRATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; CELL MOVEMENT; COLLAGENASES; GELATINASES; HUMANS; INTERFERON-BETA; INTERLEUKIN-2; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 0030483220     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400606     Document Type: Article

References (28)

1. Tuohy VK, Fritz RB, Ben-Nun A. Self-determinants in autoimmune demyelinating disease: changes in T-cell response specificity. Curr Opin Immun 1994;6:887-891
2. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10: 153-187
3. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain-barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113:1477-1489
4. Kwon EE, Prineas JW. Blood-brain-barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 1994;53:625-636
5. Goodkin DE. Interferon beta-1b. Lancet 1994;344:1057-1060
6. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15
7. Noronha A, Toscas A, Jensen MA. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-153
8. Abu-khabar KS, Armstrong JA, Ho M. Type I interferons (IFN-α and -β) suppress cytotoxin (tumor necrosis factor-α and lymphotoxin).; production by mitogen-stimulated human peripheral blood mononuclear cells. J Leukoc Biol 1992;52: 165-172
9. Leppert D, Waubant E, Galardy R, et al. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389
10. Leppert D, Hauser SJ, Kishiyama JL, et al. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J 1995;9:1473-1481
11. Xia M, Leppert D, Hauser SJ, et al. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J Immunol 1996; 156:160-167
12. Hartung HP. Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol 1995;8:191-199
13. Willoughby EW, Grochowski E, Li DKB, et al. Serial MR scanning in patients with MS: a second prospective study in relapsing patients. Ann Neurol 1989;25:43-49
14. Paty DW, Li DKB. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
15. Rosenberg GA, Kornfeld M, Estrada E, et al. TIMP-2 reduces proteolytic opening of blood-brain-barrier by type IV collagenase. Brain Res 1992;576:203-207
16. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1994;94:2177-2182
17. De Mayer E, De Mayer-Guignard J. Interferons. In: Thomson A, ed. The cytokine handbook. London: Academic, 1994:265-288
18. David M, Petricoin E, Benjamin C, et al. Requirement for MAP kinase (ERK2) activity in interferon α- and interferon β-stimulated gene expression through STAT proteins. Science 1995;269:1721-1723
19. Mackay AR, Ballin M, Pelina MD, et al. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastatis 1992;12:168-184
20. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990;265:11077-11082
21. Gohji K, Fidler IJ, Tsan R, et al. Human recombinant interferons-beta and -gamma decrease gelacinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 1994; 58:380-384
22. Fabra A, Nakajima M, Bucana CD, Fidler IJ. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation 1992;52: 101-110
23. r 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 1994;58:582-586
24. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol Today 1994;15:103-107
25. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993;192:1175-1181
26. Gearing AJH, Beckett P, Christodoulu M, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994;370:555-557
27. McGeehan GM, Becherer JD, Bast RC, et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994;370:558-561
28. Raine CS. Multiple sclerosis: TNF - revisited, with promise. Nature Med 1995;1:211-214